✦ LIBER ✦

Targeting Myeloma Stem Cells with T Cells Armed with Anti-CD3 X Anti-CD20 Bispecific Antibody (CD20BI) Prior to ASCT Leads to Development of Anti-Myeloma Immune Responses Post Autologous Stem Cell Transplant That Can Be Boosted with Targeted T Cells

✍ Scribed by L.G. Lawrence; T. Archana; A. Muneer; A.-K. Zaid; R. Voravit; Z. Jeffrey; A. Lois; P.N. Elyse; S. Dana; S.A. Patricia; M. Karen; U.P. Joseph

Book ID: 116282985
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 18
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2011.12.162

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Clinical Trial Targeting CD20+ N

Phase I Clinical Trial Targeting CD20+ Non-Hodgkin'S Lymphoma (NHL) After Autologous Stem Cell Transplant With Anti-CD3 × Anti-CD20 Bispecific Antibody Armed T Cells

✍ L.G. Lum; A. Thakur; V. Ratanatharathorn; Z. Al-Kadhimi; E. Paul; C. Skuba; P. S 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 92 KB

Immune consolidation after stem cell tra

Immune consolidation after stem cell transplant for CD20+ nonhodgkin’s lymphoma using multiple infusions of autologous activated t cells (ATC) with anti-cd3 x anti-cd20 bispecific antibody (CD20Bi) to improve graft-vs-lymphoma effects

✍ L.G. Lum; P. Davol; G. Colvin; R. Rathore; M. Abedi; E. Palushock; A. Olson; T. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Primed And Boosted Anti-Breast Cancer Tu

Primed And Boosted Anti-Breast Cancer Tumor Immunity After Autologous Peripheral Blood Stem Cell Transplant (PBSCT): In Vivo Priming With T Cells Armed With Anti-CD3 X anti-Her2/neu Bispecific Antibody (Her2Bi) Pre PBSCT And Boosting After PBSCT With Activated T Cells (ATC)

✍ L.G. Lum; A. Thakur; Z. Al-Kadhimi; M. Abidi; L. Ayash; F. Cummings; R. Rathore; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 63 KB